ifosfamide has been researched along with Carcinoma, Bronchial in 26 studies
Excerpt | Relevance | Reference |
---|---|---|
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 7.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 3.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
"The early stages of bronchial carcinoma are still a domain of operative treatment." | 2.68 | [Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. ( Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N, 1995) |
" As compared with the values obtained on day 1, on day 5 the terminal half-life and AUC values determined for IF were reduced by 30% (6." | 1.29 | Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. ( Kurowski, V; Wagner, T, 1993) |
" Both schedules resulted in a reduction in the elimination half-life with an increased total and nonrenal clearance of ifosfamide over the 5-day period." | 1.28 | Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. ( Cerny, T; Lind, MJ; Margison, JM; Thatcher, N; Wilkinson, PM, 1989) |
"The most frequent histology was squamous cell carcinoma found in 20 patients." | 1.27 | [Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. ( Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R, 1985) |
" There was a proportionate increase in the AUC for the 5-g oral dose, indicating 100% bioavailability at all three dose levels." | 1.27 | Bioavailability of ifosfamide in patients with bronchial carcinoma. ( Cerny, T; Margison, JM; Thatcher, N; Wilkinson, PM, 1986) |
"Oral ifosfamide therapy was determined to be feasible, and further studies are justified to assess the pharmacokinetics of the optimum dosage and scheduling regimens." | 1.26 | The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. ( McNiel, NO; Morgan, LR, 1981) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 21 (80.77) | 18.7374 |
1990's | 4 (15.38) | 18.2507 |
2000's | 1 (3.85) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boutemy, M | 1 |
Mispelaere, D | 1 |
Krzisch, C | 1 |
Jounieaux, V | 1 |
Liesenfeld, A | 1 |
Havemann, K | 2 |
Gropp, C | 1 |
Seifert, W | 1 |
Thomas, C | 1 |
Drings, P | 2 |
Mahnke, HG | 1 |
Westerhausen, M | 1 |
Wellens, W | 1 |
Konrad, RM | 1 |
Bryant, BM | 1 |
Jarman, M | 1 |
Ford, HT | 1 |
Smith, IE | 1 |
Valdivieso, M | 4 |
Cabanillas, F | 1 |
Keating, M | 1 |
Barkley, HT | 3 |
Murphy, WK | 4 |
Burgess, MA | 1 |
Frazier, H | 1 |
Chen, T | 1 |
Bodey, GP | 3 |
Seeber, S | 1 |
Dimitriadis, K | 1 |
Schütte, J | 1 |
Schmidt, CG | 1 |
Matthiessen, W | 2 |
Stempinski, E | 2 |
Göbel, D | 2 |
Thalmann, U | 2 |
Benjamin, RS | 2 |
Freeman, MB | 1 |
Ertel, M | 1 |
Smith, TL | 1 |
Mountain, CF | 1 |
Morgan, LR | 2 |
Holdiness, MR | 1 |
Gillen, LE | 1 |
McNiel, NO | 1 |
Wagner, W | 1 |
von Eiff, M | 1 |
Klinke, F | 1 |
Micke, O | 1 |
Rübe, C | 1 |
Willich, N | 1 |
Kurowski, V | 2 |
Wagner, T | 2 |
Cohen, MH | 1 |
Ihde, DC | 1 |
Bunn, PA | 1 |
Fossieck, BE | 1 |
Matthews, MJ | 1 |
Shackney, SE | 1 |
Johnston-Early, A | 1 |
Makuch, R | 1 |
Minna, JD | 1 |
Holoye, PY | 1 |
Glisson, BS | 1 |
Lee, JS | 1 |
Dhingra, HM | 2 |
Umsawasdi, T | 2 |
Levy, JK | 1 |
Jeffries, D | 1 |
Raber, MN | 1 |
Hong, WK | 1 |
Lind, MJ | 1 |
Margison, JM | 2 |
Cerny, T | 2 |
Thatcher, N | 2 |
Wilkinson, PM | 2 |
Banks, J | 1 |
Anderson, EG | 1 |
Smith, AP | 1 |
Manke, HG | 1 |
Gatzemeier, U | 1 |
Hossfeld, DK | 1 |
Radenbach, D | 1 |
Zschaber, R | 1 |
Loehrer, PJ | 1 |
Birch, R | 1 |
Kramer, BS | 1 |
Greco, FA | 1 |
Einhorn, LH | 1 |
Frankmann, C | 1 |
McMurtrey, MJ | 1 |
Jeffries, DG | 1 |
Welch, SR | 1 |
Li, GC | 1 |
Brock, N | 1 |
Li, JQ | 1 |
Guan, ZZ | 1 |
He, YJ | 1 |
Spitzer, G | 1 |
Farha, P | 1 |
Dicke, K | 1 |
Zander, A | 1 |
Vellekoop, L | 1 |
Chiuten, D | 1 |
Hoefer, H | 1 |
Scheef, W | 1 |
Titscher, R | 1 |
Kokron, O | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients[NCT01749072] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
8 trials available for ifosfamide and Carcinoma, Bronchial
Article | Year |
---|---|
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
Topics: Acrolein; Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Female; Hematuria; Hu | 1980 |
Role of intravenous hyperalimentation as an adjunct to intensive chemotherapy for small cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bon | 1981 |
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronc | 1995 |
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Bronchoge | 1997 |
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin | 1979 |
Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic | 1986 |
High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, | 1986 |
[Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
Topics: Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Female; Humans | 1974 |
18 other studies available for ifosfamide and Carcinoma, Bronchial
Article | Year |
---|---|
[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 2005 |
[3 multicenter phase II studies of the treatment of small cell bronchogenic carcinoma (incl. AIO studies BI + BII)].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Ca | 1984 |
Combination chemotherapy of small-cell bronchogenic carcinoma with etoposide (VP-16), ifosfamide and vindesine (VPIV), and with adriamycin, cis-platinum and vincristine (APO).
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug | 1982 |
Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carcinoma, Bronch | 1984 |
Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bro | 1984 |
Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cyclophosphamide; Doxorubic | 1983 |
N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.
Topics: Acetates; Acetylcysteine; Biological Availability; Carcinoma, Bronchogenic; Chemical Phenomena; Chem | 1983 |
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos | 1983 |
The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
Topics: Administration, Oral; Adult; Biological Availability; Carcinoma, Bronchogenic; Cyclophosphamide; Fem | 1981 |
Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Topics: Acetaldehyde; Adult; Aged; Carcinoma, Bronchogenic; Chromatography, Gas; Chromatography, High Pressu | 1993 |
Ifosfamide with mesna uroprotection in the management of lung cancer.
Topics: Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans | 1990 |
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.
Topics: Administration, Oral; Adult; Aged; Alkylation; Carcinoma, Bronchogenic; Humans; Ifosfamide; Injectio | 1989 |
Failure of response to ifosfamide in squamous cell bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Drug Resistance; Humans; Ifosfamide; Lung Neoplas | 1989 |
[Treatment of non-small-cell bronchial carcinoma with cisplatin, ifosfamide, vindesine and VP 16].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic | 1985 |
[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug | 1985 |
Long-term effects of intravenous hyperalimentation administered during intensive chemotherapy for small cell bronchogenic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcino | 1987 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Bioavailability of ifosfamide in patients with bronchial carcinoma.
Topics: Administration, Oral; Aged; Biological Availability; Carcinoma, Bronchogenic; Female; Humans; Ifosfa | 1986 |